Inhibrx Biosciences, Inc. (INBX)
NASDAQ: INBX · Real-Time Price · USD
83.30
-4.45 (-5.07%)
At close: Nov 13, 2026, 4:00 PM EST
79.56
-3.74 (-4.49%)
After-hours: Nov 13, 2026, 7:30 PM EST
Inhibrx Biosciences Employees
As of December 31, 2025, Inhibrx Biosciences had 110 total employees, including 109 full-time and 1 part-time employees. The number of employees decreased by 51 or 31.68% compared to the previous year. That makes Inhibrx Biosciences the 30,901st largest employer in the world and 3,941st in the United States.
Employees
110
Change (1Y)
-51
Growth (1Y)
-31.68%
Revenue / Employee
$18,182
Profits / Employee
-$1,287,800
Market Cap
1.23B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 110 | -51 | -31.68% | 109 | 1 |
| Dec 31, 2024 | 161 | -11 | -6.40% | 156 | 5 |
| Mar 31, 2024 | 176 | - | - | 170 | 6 |
| Dec 31, 2023 | 172 | - | - | 166 | 6 |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| UroGen Pharma | 300 |
| Kardigan | 241 |
| Omeros | 175 |
| Alpha Tau Medical | 121 |
| Silence Therapeutics | 88 |
| Vor Biopharma | 76 |
| GH Research | 73 |
INBX News
- 14 hours ago - Inhibrx files automatic mixed securities shelf - TheFly
- 15 hours ago - Inhibrx reports Q3 EPS ($2.46), consensus ($2.36) - TheFly
- 15 hours ago - Inhibrx Reports Third Quarter 2026 Financial Results - PRNewsWire
- 15 hours ago - Inhibrx Biosciences Earnings release: Q3 2026 - Filings
- 15 hours ago - Inhibrx Biosciences Quarterly report: Q3 2026 - Filings
- 4 weeks ago - Inhibrx Announces Participation in Upcoming Scientific Conferences - PRNewsWire
- 7 weeks ago - Inhibrx director buys $500K in common stock - TheFly
- 2 months ago - Inhibrx's combination cancer drug shrinks tumors in mid-stage head and neck cancer study - Reuters